Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
0.666
+0.013 (1.98%)
Nov 21, 2024, 10:44 AM EST - Market open
Predictive Oncology Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Predictive Oncology.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for POAI is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +350.79% | Aug 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +14,926.30% | Jun 30, 2021 |
Financial Forecast
Revenue This Year
1.58M
from 1.78M
Decreased by -11.30%
Revenue Next Year
9.52M
from 1.58M
Increased by 502.91%
EPS This Year
-2.07
from -3.48
EPS Next Year
-0.16
from -2.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 1.6M | 9.8M | 16.2M |
| Avg | 1.6M | 9.5M | 15.8M |
| Low | 1.5M | 9.1M | 15.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -8.7% | 520.6% | 70.4% |
| Avg | -11.3% | 502.9% | 65.5% |
| Low | -14.8% | 479.2% | 59.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.13 | -0.17 | 0.05 |
| Avg | -2.07 | -0.16 | 0.05 |
| Low | -1.99 | -0.16 | 0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.